Introduction And Rationale

Hexavalent vaccines offer combined protection against six major vaccine-preventable diseases: diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis.
Target diseases remain major pediatric concerns; pertussis causes up to 100,000 cases annually in children under five, Haemophilus influenzae type b drives pneumonia and meningitis, hepatitis B causes chronic liver disease, and polio requires sustained IPV administration for global certification.
Formulated as a single, fully liquid injection, optimizing cold-chain logistics and conserving health-worker time.
Reduces injection burden per visit from two or three down to one.
Decreased injections lower parental hesitancy, addressing the national dropout rate of 12.6% between the first and third pentavalent doses.

Current Status And Government Guidelines

Hexavalent vaccines are not yet integrated into the nationwide Universal Immunization Programme as of May 2026.
Current national schedule continues to utilize the pentavalent vaccine alongside fractional inactivated polio vaccine and oral polio vaccine administered at 6, 10, and 14 weeks.
National Technical Advisory Group on Immunization currently prioritizes typhoid conjugate and HPV vaccines, delaying formal hexavalent transition.

Strongly endorses indigenous whole-cell pertussis-based hexavalent vaccines for primary immunization in private practice.
Recommends a 3-dose primary series administered at 6, 10, and 14 weeks.
Advises subsequent DPT boosters at 16 to 18 months and 5 years of age.
Preterm and low-birth-weight infants require a birth hepatitis B dose followed by three subsequent hexavalent doses.

Indian Phase 3 trials confirm non-inferior immunogenicity compared to separate pentavalent and IPV administration.
Achieves seroprotection rates exceeding 95% across all included antigens.
Demonstrates excellent safety profile; mild local reactions occur in under 20% of cases without any excess serious adverse events.
Long-term persistence studies confirm durable immunity lasting up to 4 to 5 years post-booster.
Real-world international rollout data indicates 5% to 8% coverage gains and reduced cold-chain burden.
Cost-effectiveness models strongly favor hexavalent implementation in high-dropout settings.

Higher per-dose cost presents a primary barrier compared to free pentavalent vaccines.
Nationwide transition requires extensive regulatory harmonization and health worker retraining.
Expansion of adverse event surveillance via digital platforms like U-WIN is mandatory.
Indigenous manufacturing capacity guarantees future domestic supply without import dependency.